Abstract: AIM: To investigate the effects of a novel thiazolidinedione ANY₂ on glycometabolism in HepG₂ cells .METHODS: HepG₂ cells are exposed to high concentrations of insulin for 24 h to build the model of insulin-resistance (IR-HepG₂) .The effects of ANY₂ , including glucose consumption (GC) , glucone-ogenesis and glucolysis were tested in this model.RESULTS: ANY₂ could dose-dependently enhance GC in IR-HepG₂ cells at high, medium and low levels of glucose.Compared with Modle Group, ANY₂ increased IR-HepG₂ cells glycogen synthesis significantly only in high dose group .It inhibited gluconeogenesis from lac-tic acid, but increased the production of lactic acid and the activity of pyruvate kinase (PK) in glucolysis.CONCLUSION: Compound ANY2 has remarkable ef-fects on improving glycometabolism in IR-HepG₂ cells.

Key words: glycometabolism, HepG₂, insulin re-sistance